New options for drug treatment of obesity in patients with Type 2 diabetes.
Kennedy
R L
RL
Department of Medicine, James Cook University, Queensland, Australia.
Khoo
E Y H
EY
D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D001067:Appetite Depressants / Q000627:therapeutic use; D002186:Cannabinoids / Q000037:antagonists & inhibitors; D003503:Cyclobutanes / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007783:Lactones / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D000077403:Orlistat; D010880:Piperidines / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D000077285:Rimonabant
D019440:Anti-Obesity Agents; D001067:Appetite Depressants; D002186:Cannabinoids; D003503:Cyclobutanes; D007004:Hypoglycemic Agents; D007783:Lactones; D010880:Piperidines; D011720:Pyrazoles; D000077403:Orlistat; D000077285:Rimonabant; C058254:sibutramine